A new drug has shown promising results in a pancreatic cancer trial, with reports indicating it doubles one-year survival rates. The treatment, described as a potential game-changer for one of the deadliest cancers, may involve combination therapy and has been found to reduce side effects in some cases. The exact nature and outcomes of the treatment are still being reported, with some outlets specifying its effectiveness in patients with metastatic pancreatic cancer.